Are There Differences Between Carriers of Haemophilia A & B?

Status Completed

Clinical Trial Summary

This study aims to develop a systematic genetic screening strategy for (potential) female carriers of haemophilia by identifying as many female carriers as possible within the families of haemophilia patients regularly followed at Cliniques universitaires Saint-Luc (CUSL) and to search for differences between female carriers of haemophilia A (HA) and B (HB).

Clinical Trial Description

In order to complete our local registry of female carriers, the family trees of haemophilia patients will be systematically updated during their follow-up consultations at the haemophilia centre. Female carriers not yet known in our centre, identified by the updating of pedigrees, will be invited to present themselves in the haematology consultation and to participate in the study by means of an invitation and information letter which will be given/sent to them by the index haemophilia patient. Female carriers already known for whom missing data and/or the indication of regular follow-up have been identified during the file review will also be invited to attend a consultation within the framework of the study. At these consultations, (potential) carriers will be given information about haemophilia, the mode of genetic transmission and the implications of carrier status on patients' lives (bleeding prevention, reproductive choices, current haemophilia treatments and future prospects). We will then determine the bleeding phenotype of each patient by taking a comprehensive bleeding history. With the consent of the participants concerned, the familial genetic variant responsible for haemophilia will be sought in them in order to definitively establish their carrier status. The basal level of coagulation factors VIII (HA)/IX (HB) will also be determined. If a deficiency is found, haemostatic treatment adapted to the patient's situation will be initiated and clinical follow-up outside the study recommended. After completion of the data collection, the data will be analyzed and compared between HA and HB carriers in order to identify possible differences between these two populations. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05217992
Study type	Observational
Source	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Contact
Status	Completed
Phase
Start date	May 25, 2021
Completion date	April 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05617209` - In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients
Completed	`NCT05039008` - Restricting Blood Flow in Improving Muscle Strength in Patients With Hemophilic Arthropathy	N/A
Recruiting	`NCT04398628` - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed	`NCT02546622` - ATHN 2: Factor Switching Study
Terminated	`NCT02586012` - Weight-based Dosing in Hemophilia A	Phase 2
Completed	`NCT02165462` - Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy	N/A
Unknown status	`NCT02433782` - Myofascial Therapy in Patients With Hemophilic Arthropathy	N/A
Unknown status	`NCT02165592` - Assessment of Proprioceptive and Functional Characteristics in Patients With Hemophilia	N/A
Completed	`NCT01232634` - Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles	Phase 2
Completed	`NCT05104164` - Self-myofascial Release in Hemophilic Ankle Arthropathy	N/A
Terminated	`NCT01191372` - First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients	Phase 1
Completed	`NCT05173129` - Posture Analysis for Patients With Haemophilia	N/A
Completed	`NCT03818529` - ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Withdrawn	`NCT03996486` - Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia	Phase 1
Completed	`NCT01708564` - A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B	Phase 1
Completed	`NCT03842605` - Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia	N/A
Completed	`NCT05549843` - Manual Therapy in the Treatment of Hemophilic Arthropathy of the Ankle	N/A
Recruiting	`NCT06010953` - SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment	Phase 1/Phase 2
Completed	`NCT05027230` - A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor	Phase 1/Phase 2
Not yet recruiting	`NCT06014320` - Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Are There Differences Between Carriers of Haemophilia A and B?

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms